Chemotherapy Disrupted Immune Response in Gastric Cancer
New research published September 23, 2026, reveals how chemotherapy triggers Epstein-Barr virus reactivation.
Updated on Sept. 23, 2026 in Cancer
A study published on September 23, 2026, found that neoadjuvant chemotherapy disrupts the formation of tertiary lymphoid structures in Epstein-Barr virus-associated gastric cancer. This process reduces the treatment's overall efficacy.
Why it matters
The findings explain why chemotherapy has shown limited success in treating this specific cancer subtype, as it inadvertently promotes immune-suppressive environments. These insights could lead to new strategies to improve patient outcomes by targeting the virus-neutrophil interaction.
Researchers utilized 144 samples for an EBVaGC cohort analysis and 11 samples for spatial transcriptomics. A single-cell atlas was also constructed using 77 distinct samples to map immune cell behavior.
The details
Chemotherapy induces reactivation of the Epstein-Barr virus, which subsequently activates neutrophil pattern recognition receptors. This results in the formation of neutrophil extracellular traps that impair lymphocyte migration and stop tertiary lymphoid structure maturation.
Timeline
September 23, 2026: The research findings were formally published.
The Big Picture
This research follows the established significance of the CXCR4-CXCL12 axis in tumor microenvironments. By detailing how this pathway facilitates immune suppression, the study bridges gaps between viral oncology and modern immunometabolism.
This research provides a clearer understanding of why certain chemotherapy regimens may not be effective for specific gastric cancer patients. It highlights the importance of potential future screening to identify Epstein-Barr virus status before beginning treatment.
The takeaway
Understanding how viral reactivation influences immune cell behavior is critical for improving cancer survival rates. Patients and clinicians should discuss how individual tumor profiles may impact the efficacy of standard chemotherapy protocols.
Further reading
For more on the latest research in oncology, visit our Cancer section.
More information
View the complete findings in the peer-reviewed research article.
Source note: This article includes information reported by Nature.
